Similar articles

• Pneumococcal vaccination for acute otitis media.

  Marchetti F, Bua J, Ventura A. Marchetti F, et al. Lancet. 2006 Jun 10;367(9526):1897; author reply 1898. doi: 10.1016/S0140-6736(06)68832-6. Lancet. 2006. PMID: 16765748 No abstract available.
• Effect of conjugate pneumococcal vaccine on recurrent acute otitis media.

  Esposito S, Principi N. Esposito S, et al. Lancet. 2003 Sep 27;362(9389):1080-1; author reply 1081. doi: 10.1016/S0140-6736(03)14430-3. Lancet. 2003. PMID: 14522551 No abstract available.
• Management of otitis media with antimicrobial agents.

  Klein JO. Klein JO. Curr Clin Top Infect Dis. 2000;20:174-88. Curr Clin Top Infect Dis. 2000. PMID: 10943524 Review. No abstract available.
• Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study.

  Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Poolman J, Prieels JP, Schuerman L. Prymula R, et al. Lancet. 2006 Mar 4;367(9512):740-8. doi: 10.1016/S0140-6736(06)68304-9. Lancet. 2006. PMID: 16517274 Clinical Trial.
• Brief review of the clinical effectiveness of PREVENAR against otitis media.

  Fletcher MA, Fritzell B. Fletcher MA, et al. Vaccine. 2007 Mar 22;25(13):2507-12. doi: 10.1016/j.vaccine.2006.09.027. Epub 2006 Sep 20. Vaccine. 2007. PMID: 17011085 Review.